NCT06136351View on ClinicalTrials.gov

A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

November 15, 2023

Primary Completion Date

November 1, 2027

Study Completion Date

November 1, 2027

Conditions
Lymphoma, Mantle-Cell
Interventions
DRUG

Zanubrutinib

160 mg bid po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during the 2 years of follow-up

DRUG

Rituximab

375 mg/m\^2 ivgtt, D0 of each 28-day cycle

DRUG

Bendamustin

90mg/m\^2 ivgtt, D0 of each 28-day cycle

Trial Locations (1)

200020

RECRUITING

Ruijin Hospital, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER